A Almirall SA
A
Open
SectorHealthcare
11.24 3.12
Overview
Share price change
24h
Min
10.86
Max
11.24
Income | -4.3M 15M |
|---|---|
Sales | -257M 291M |
P/E Sector Avg | 57.895 49.888 |
EPS | 0.071 |
Dividend yield | 1.71 |
Profit margin | 5.258 |
Employees | 2,108 |
EBITDA | 135M 237M |
Dividend yield Sector Avg | 1.71% 2.38% |
|---|---|
Next Earnings | 24 lip 2026 |
Market Cap | -163M 2.4B |
|---|---|
Previous open | 8.12 |
Previous close | 11.24 |
News Sentiment
By Acuity
50%
50%
155 / 344 Ranking in Healthcare
Almirall SA Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Almirall SA Forecast
Sentiment
By Acuity
155 / 344 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
